Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893707 | 0.81 | HIF1A (0.42) | DUT | |
| SCHEMBL4891900 | 0.78 | KDM4E (0.33) | MEN1KMT2ASLC29A1 | |
| SCHEMBL4903657 | 0.77 | SLC29A1 (0.38) | MEN1KMT2ASLC29A1 | |
| SCHEMBL4894592 | 0.77 | MEN1 (0.36) | MEN1KMT2ASLC29A1 | |
| SCHEMBL24999134 | 0.72 | ADORA2A (0.45) | MEN1KMT2ASLC29A1 | |
| SCHEMBL6177913 | 0.71 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL1106478 | 0.69 | PDE4A (0.43) | MEN1KMT2ACCNE1CDK2 | |
| SCHEMBL6577204 | 0.67 | CYP2C19 (0.39) | DUTMEN1KMT2A | |
| SCHEMBL14175361 | 0.66 | ADORA2A (0.59) | — | |
| SCHEMBL19306551 | 0.64 | SYK (0.38) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318878-A1 | Antibacterial Agents | RANBAXY LABORATRIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
| EP-1812455-A2 | ERYTHROMYCIN A DERIVATIVES AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006035301-A2 | ERYTHROMYCIN A DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318878-A1 | Antibacterial Agents | MLX, MGAM, CAT | DUT 3176/4885MEN1 3417/4885KMT2A 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.